BeyondSpring
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 36
- Market Cap
- -
- Introduction
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in Florham Park, NJ.
BeyondSpring's Plinabulin Shows Promising Survival Benefits in Lung Cancer and Strategic Advances in Protein Degradation
• BeyondSpring's Plinabulin demonstrated statistically significant survival benefits in second and third-line non-small cell lung cancer (EGFR wild-type) patients, with results published in The Lancet Respiratory Medicine.
• Phase 2 studies show Plinabulin's potential to resensitize tumors that have progressed on PD-1/PD-L1 inhibitors in metastatic NSCLC, addressing a significant unmet need as 60% of patients develop resistance to checkpoint inhibitors.
• SEED Therapeutics, co-founded by BeyondSpring, secured a research collaboration with Eisai worth up to $1.5 billion and received FDA Rare Pediatric Disease and Orphan Drug Designations for its RBM39 degrader.
© Copyright 2025. All Rights Reserved by MedPath